Here's a linkto Gu, Rosen and a couple of other industry people talking about the CBD situation in China. The video is old (Nov 2020) and outdated (China prohibited CBD use in cosmetics and TCM shortly after the video was published), but contains some interesting insights on market structures and other stuff e.g.,
- The Panel discusses how tightly the China government controls hemp cultivation and CBD extraction licences (virtually all the ones that do exist are held by large Chinese public companies)
- The Panel discusses the 'genetic bottleneck' that's holding back the Chinese CBD industry. In the US, hemp CBD yields are up to 20% but in China they rarely exceed 1% (Gu notes our Yunnan farm has achieved yields of 10%)
- Someone mentions a new hemp strain (e.g., a newly-developed high-yield CBD strain) must be trialled for a three-year period before the Chinese government will approve it for production
- At the approx. 40min mark, Gu outlines his strategy for running a CBD operation in China: (a) be low-profile, (b) move slowly (c) refrain from advocacy, and (d) cultivate connections with the right partners.
- Forums
- ASX - By Stock
- BP8
- SCU general
SCU general
-
- There are more pages in this discussion • 41 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BP8 (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.954M |
Open | High | Low | Value | Volume |
0.1¢ | 0.1¢ | 0.1¢ | $231 | 231.4K |
Featured News
BP8 (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
Previous Video
Next Video
SPONSORED BY The Market Online